174 related articles for article (PubMed ID: 23915193)
21. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
23. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
24. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone.
Naot D; Bava U; Matthews B; Callon KE; Gamble GD; Black M; Song S; Pitto RP; Cundy T; Cornish J; Reid IR
J Bone Miner Res; 2007 Feb; 22(2):298-309. PubMed ID: 17129176
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
[TBL] [Abstract][Full Text] [Related]
26. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
29. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
30. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
31. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
32. Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type.
Auziņa D; Beinaroviča I; Janicka-Kupra B; Lejniece S; Lejnieks A; Groma V
Exp Oncol; 2020 Dec; 42(4):285-288. PubMed ID: 33355872
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
[TBL] [Abstract][Full Text] [Related]
34. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
35. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
36. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass.
Morvan F; Boulukos K; Clément-Lacroix P; Roman Roman S; Suc-Royer I; Vayssière B; Ammann P; Martin P; Pinho S; Pognonec P; Mollat P; Niehrs C; Baron R; Rawadi G
J Bone Miner Res; 2006 Jun; 21(6):934-45. PubMed ID: 16753024
[TBL] [Abstract][Full Text] [Related]
37. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
He J; Liu Z; Zheng Y; Qian J; Li H; Lu Y; Xu J; Hong B; Zhang M; Lin P; Cai Z; Orlowski RZ; Kwak LW; Yi Q; Yang J
Cancer Res; 2012 Dec; 72(24):6393-402. PubMed ID: 23066034
[TBL] [Abstract][Full Text] [Related]
38. TRAIL produced from multiple myeloma cells is associated with osteolytic markers.
Kawano Y; Ueno S; Abe M; Kikukawa Y; Yuki H; Iyama K; Okuno Y; Mitsuya H; Hata H
Oncol Rep; 2012 Jan; 27(1):39-44. PubMed ID: 21993926
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Fowler JA; Mundy GR; Lwin ST; Edwards CM
Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
[TBL] [Abstract][Full Text] [Related]
40. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]